# IL17-deficient NOD mice are protected from autoimmune diabetes due to decreased antigen presentation and T cell activation

**Authors:** James A. Pearson, Yangyang Li, Juan Huang, Jian Peng, F. Susan Wong, Li Wen

PMC · DOI: 10.3389/fimmu.2025.1728313 · 2026-01-12

## TL;DR

Removing IL-17 in mice prevents diabetes by reducing immune cell activation and antigen presentation in the gut.

## Contribution

Shows IL-17 deficiency protects against diabetes via altered gut microbiota and reduced T cell activation.

## Key findings

- IL-17-deficient NOD mice are protected from autoimmune diabetes.
- Intestinal epithelial cells from these mice show reduced antigen presentation to CD8+ T cells.
- Changes in gut microbiota mediate the protective effect of IL-17 deficiency.

## Abstract

IL-17 is a key cytokine helping preserve the intestinal barrier against infections; however, the T cells that primarily secrete IL-17 (Th17) can promote the development of autoimmunity. In Type 1 diabetes, the role of IL-17 is less well understood, with many studies evaluating the role of IL-17, without considering changes within the intestine. Furthermore, therapeutically targeting IL-12/IL-23 (upstream of IL-17) or IL-17 directly can help preserve insulin-producing beta cells in those newly diagnosed with Type 1 diabetes. Thus, there is a need to better understand how IL-17 may modulate susceptibility to Type 1 diabetes by linking intestinal changes to type 1 diabetes development.

We studied IL-17-deficient NOD mice to understand the role of IL-17 in mediatingsusceptibility to Type 1 diabetes in vivo and in vitro.

Our study showed that IL-17-deficient NOD mice were protected from autoimmune diabetes, and in vivo adoptive transfer studies showed that both immune and non-immune cells are important for modulating diabetes development. We found significant reductions in both regulatory T cells and inflammatory T-bet-expressing CD8+ T cells, while Type 3 Innate Lymphoid Cells (ILC3s) were expanded. These changes were found to be mediated through altered gut microbiota composition of the IL-17-deficient NOD mice. Finally, we demonstrated that intestinal epithelial cells from IL-17-deficient NOD mice were less able to present autoantigen to autoreactive CD8+ T cells, with reduced proinflammatory cytokine secretion. This effect was specific to IL-17 deficiency, as addition of exogenous IL-17 resulted in improved antigen presentation to autoreactive CD8+ T cells.

Together, our data suggest a novel role for IL-17 in modulating epithelial cell function and antigen presentation within the intestinal tissue, resulting in reduced autoantigen-specific T cell responses and enhanced protection from autoimmune diabetes. Better understanding of how targeted IL-17 blockade could be administered to the intestine may help better prevent the development of Type 1 diabetes.

## Linked entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605]
- **Proteins:** IL17A (interleukin 17A), TBX21 (T-box transcription factor 21), CD8A (CD8 subunit alpha)
- **Diseases:** Type 1 diabetes (MONDO:0005147)

## Full-text entities

- **Genes:** Ccl4 (C-C motif chemokine ligand 4) [NCBI Gene 20303] {aka AT744.1, Act-2, MIP-1B, Mip1b, Scya4}, Cldn2 (claudin 2) [NCBI Gene 12738], Itgax (integrin alpha X) [NCBI Gene 16411] {aka Cd11c, Cr4, N418}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, H2 (histocompatibility-2, MHC) [NCBI Gene 111364] {aka H-2, MHC-II}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Tbx21 (T-box 21) [NCBI Gene 57765] {aka TBT1, Tbet, Tblym}, Cd8a (CD8 subunit alpha) [NCBI Gene 12525] {aka Ly-2, Ly-35, Ly-B, Lyt-2}, Sell (selectin, lymphocyte) [NCBI Gene 20343] {aka CD62L, L-selectin, LAM-1, LECAM-1, LECAM1, Lnhr}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Cd19 (CD19 antigen) [NCBI Gene 12478], Trav6-3 (T cell receptor alpha variable 6-3) [NCBI Gene 328483] {aka Gm13948, Gm193, Gm4, TCR}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, H2-K1 (histocompatibility 2, K1, K region) [NCBI Gene 14972] {aka H-2K, H-2K(d), H2-D1, H2-K, K-f}, I-ag7 (MHC class II molecule I-Ag7) [NCBI Gene 100909391], Gata3 (GATA binding protein 3) [NCBI Gene 14462] {aka Gata-3, jal}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Tcrb (T cell receptor beta chain) [NCBI Gene 21577] {aka TCRbeta, Tib}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Il23a (interleukin 23, alpha subunit p19) [NCBI Gene 83430] {aka IL-23, p19}, Il22 (interleukin 22) [NCBI Gene 50929] {aka IL-22, IL-22a, ILTIFa, If2b1, Iltif}, Il12b (interleukin 12b) [NCBI Gene 16160] {aka Il-12b, Il-12p40, Il12p40, p40}, Il2ra (interleukin 2 receptor, alpha chain) [NCBI Gene 16184] {aka CD25, Il2r, Ly-43}
- **Diseases:** cancer (MESH:D009369), rheumatoid arthritis (MESH:D001172), islet autoimmunity (MESH:D007516), IL-17-deficiency (MESH:C535750), infection (MESH:D007239), autoimmune (MESH:D001327), NOD (MESH:D009765), inflammatory (MESH:D007249), dislocation (MESH:D004204), multiple sclerosis (MESH:D009103), glycosuria (MESH:D006029), cervical (MESH:D002575), NOD (MESH:D020191), intestinal bowel disease (MESH:D007410), Type 1 diabetes (MESH:D003922), Diabetes (MESH:D003920)
- **Chemicals:** short chain fatty acids (MESH:D005232), thymidine (MESH:D013936), Mitomycin-c (MESH:D016685), FITC-dextran (MESH:C015219), isopropanol (MESH:D019840), isoamyl alcohol (MESH:C029683), HBSS (-), silica (MESH:D012822), Ustekinumab (MESH:D000069549), Trizol (MESH:C411644), formalin (MESH:D005557), SDS (MESH:D012967), HEPES (MESH:D006531), water (MESH:D014867), PBS (MESH:D007854), hemotoxylin (MESH:D006416), phenol (MESH:D019800), blood glucose (MESH:D001786), 3H (MESH:D014316), eosin (MESH:D004801), zirconium (MESH:D015040), chloroform (MESH:D002725), TE (MESH:D013691), Gentamycin (MESH:D005839), ethanol (MESH:D000431), EDTA (MESH:D004492)
- **Species:** Clostridia (class) [taxon 186801], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Escherichia coli (E. coli, species) [taxon 562], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), BDC2.5 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_X943)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12850519/full.md

---
Source: https://tomesphere.com/paper/PMC12850519